Parvovirus B19: Difference between revisions
3amrbadawy (talk | contribs) (parvo clinical) |
Neil.m.young (talk | contribs) (Text replacement - "==Diagnosis==" to "==Evaluation==") |
||
| (12 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*In children: causes | *In children: causes [[Erythema infectiosum]] (Fifth disease) | ||
*In transplant patients on immunosuppressive drugs: causes RBC aplasia. | *In transplant patients on immunosuppressive drugs: causes RBC aplasia. | ||
**Short-lived, may not be discovered | **Short-lived, may not be discovered | ||
| Line 7: | Line 7: | ||
==Clinical Features== | ==Clinical Features== | ||
*[[Erythema infectiosum (fifth disease)]] | *[[Erythema infectiosum (fifth disease)]] | ||
*[[ | *Most contagious during the phase of active viral replication and viral shedding, which occurs approximately 5 to 10 days after exposure and usually lasts approximately 5 days | ||
*Complications | |||
**Arthropathy | |||
**[[Aplastic anemia]] | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
*[[Roseola]] | |||
*[[Measles]] | |||
*[[Rubella]] | |||
*Enteroviral infections | |||
*Group A Streptococcal infections | |||
== | ==Evaluation== | ||
*Diagnosis is clinical usually through clinical presentation | |||
*IgM testing is recommended for immunocompromised patients. | |||
==Management== | ==Management== | ||
*Parvovirus is usually self-limiting and requires no further treatment. | |||
*Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia. | |||
==Disposition== | ==Disposition== | ||
| Line 22: | Line 34: | ||
==References== | ==References== | ||
*Fish RM, Massad MG. The Transplant Patient. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011. | |||
*Place R, Lagoc AT, Mayer TA, Lawlor CJ. Oncology and Hematology Emergencies in Children. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011 | |||
<references/> | <references/> | ||
[[Category:ID]] | |||
Latest revision as of 10:59, 24 July 2016
Background
- In children: causes Erythema infectiosum (Fifth disease)
- In transplant patients on immunosuppressive drugs: causes RBC aplasia.
- Short-lived, may not be discovered
- Parvovirus only replicated in erythroid progenitor cells
Clinical Features
- Erythema infectiosum (fifth disease)
- Most contagious during the phase of active viral replication and viral shedding, which occurs approximately 5 to 10 days after exposure and usually lasts approximately 5 days
- Complications
- Arthropathy
- Aplastic anemia
Differential Diagnosis
Evaluation
- Diagnosis is clinical usually through clinical presentation
- IgM testing is recommended for immunocompromised patients.
Management
- Parvovirus is usually self-limiting and requires no further treatment.
- Management should be targeted at reducing symptoms, such as using anti-inflammatory medications for arthropathy or performing transfusions for aplastic anemia.
Disposition
See Also
External Links
References
- Fish RM, Massad MG. The Transplant Patient. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011.
- Place R, Lagoc AT, Mayer TA, Lawlor CJ. Oncology and Hematology Emergencies in Children. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. New York, NY: McGraw-Hill; 2011